Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Figures corrected afterwards (2023).
Gross margin
€ -105,252
▲ 8% vs 2024
Profit
Caution€ -690,490
▼ 53% vs 2024
Debts
Low€ 222,178
▲ 30% vs 2024
CANCER STATE THERAPEUTICS from Charleroi, company number BE0793113273, closed financial year 2025 with a result of € -690,490 after tax. For that financial year CANCER STATE THERAPEUTICS recorded a gross margin of € -105,252 and equity of € 3.7 million. Compared with financial year 2024, the result moved from € -451,570 to € -690,490. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 15, 2026.
What happened at CANCER STATE THERAPEUTICS?
What happened at CANCER STATE THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 690,490. Source: NBB ↗
- Pierre Chevalier became a director. NBB
- François Delvaux became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 330,453 loss in 2023 to € 690,490 loss in 2025.
A new publication or filing at CANCER STATE THERAPEUTICS? We notify you, reason included.
Follow CANCER STATE THERAPEUTICSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind CANCER STATE THERAPEUTICS are Ahmed Fahim, Gaetan Waucquez, Pierre Chevalier, Jean-Claude Marian, Cédric Blanpain and François Delvaux. The same people are also behind ARLON 32, Cristallerie du Val Saint Lambert, GEORGE FORREST EUROPE, VOSSENSTEERT and GROUPE FORREST INTERNATIONAL.
Directors
According to the 2025 annual accounts
Ahmed Fahim
Director
Pierre Chevalier
Director
Also active at: Cristallerie du Val Saint Lambert, GEORGE FORREST EUROPE, VOSSENSTEERT +1 more
since 2025
Jean-Claude Marian
Director
Cédric Blanpain
Managing director
François Delvaux
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Rue Auguste Piccard 48
6041 Charleroi
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
SYNABS
€ 742,551 gross margin · 2025
European Infrared Technologies
€ 53,354 gross margin · 2024
HEARTKINETICS
€ -463,720 gross margin · 2022
Genflow Biosciences
€ -264,246 gross margin · 2025
NEUVASQ BIOTECHNOLOGIES
€ 641,586 gross margin · 2025
+1 more
Details
- Company number
- 0793.113.273
- VAT number
- BE 0793.113.273
- Registered office
- Rue Auguste Piccard 48, 6041 Charleroi
- Names & denominations
- CANCER STATE THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2022
- Peppol
- Active · Active since 9 Nov 2022
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied